KLK3 and prostate carcinoma: A derivative of MCP, PectaSol-MCP was evaluated in clinical trial phase II (NCT01681823) regarding its capability to improve prostate-specific antigen (PSA) kinetics in men with increased PSA levels and biochemically relapsed prostate cancer, PSA progression was inhibited in 58% of patients.